Domestic markets navigated a volatile week, ending near all-time highs. Bajaj Finance filed for a Rs 7,000 crore IPO, Kronox Lab to debut with 30% premium, Godawari Power eyes share buyback, Dr Reddy’s unit gets FDA observations, and Jubilant Pharmova faces FDA scrutiny.
HFCL’s AI, data centre exposure drives Nuvama’s Buy call; target implies 56% upside
Nuvama has initiated coverage on HFCL with a ‘Buy’ rating and a target price of Rs 380, implying a 56% upside from its reference price